HOME >> BIOLOGY >> NEWS
Protein interactions targets for Huntington disease therapy

HOUSTON (May 11, 2007) -- The identification of more than 200 new proteins that interact with the mutated protein that causes Huntingtons disease opens the door to developing treatments for the fatal neurodegenerative disorder, said a Baylor College of Medicine researcher who took part in the work that appears online today in the journal Public Library of Science Genetics.

BCM scientists actually determined which proteins among the list of more than 200 identified at Buck Institute modify the effect of the Huntingtons protein. The Buck Institute is located in Novato, California.

Huntingtons disease is a devastating, fatal neurological disorder that affects an estimated 30,000 Americans. It is dominantly inherited, which means that if a person inherits a single copy of the gene from a parent, that person will develop the disease usually in middle age. Children born to parents who go on to develop Huntingtons disease have a 50:50 chance of having the disease themselves. Musician Woody Guthrie was among its best known sufferers.

Many of the proteins that interact with Huntingtons are modulators of its toxicity, said Dr. Juan Botas, associate professor of molecular and human genetics at BCM and a senior author of the paper. This could also be a way to look for and identify factors that modulate a number of proteins involved in other neurodegenerative disease.

Modulating means that the interacting protein affects the deadly symptoms caused by Huntingtons, he said. Some of the interactive proteins might cause a person to develop the disease later; others could actually make the symptoms appear earlier or to be more severe.

When you tinker with some of these genes, you find that some of them improve the symptoms. These could be potential therapeutic targets, said Botas. When you tinker with others, it makes the Huntingtons more aggressive. These might be ones that accelerate the age of disease onset. Not everyone with
'"/>

Contact: Graciela Gutierrez
ggutierr@bcm.edu
713-798-4710
Baylor College of Medicine
10-May-2007


Page: 1 2

Related biology news :

1. Protein chatter linked to cancer activation
2. Coming soon -- Protein synthesis without amino acids?
3. Protein pulling -- Learning how proteins fold by pulling them apart
4. Protein enables discovery of quantum effect in photosynthesis
5. Protein found that slows hepatitis C growth in liver cells
6. Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex
7. Protein averts cell suicide but might contribute to cancer
8. Protein structures for the entire yeast proteome
9. Protein overexpression at heart of heart failure
10. Protein sciences
11. Protein identified that regulates effectiveness of Taxol chemotherapy in breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/2/2019)... ... November 01, 2019 , ... Stay on top of current hot topics ... Access to all webinars is free, so be sure to register today to save ... http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , November 14 ...
(Date:10/30/2019)... ... October 30, 2019 , ... Analogous ... are encoded by the ordering of monomer residues into specific sequences along ... sidechain attachment to the backbone amide-nitrogen atoms. They are resistant to protease ...
(Date:10/26/2019)... SAN FRANCISCO (PRWEB) , ... October 23, 2019 ... ... Chief Operating Officer, Christina Hughes , to its executive leadership team. , ... Medrio’s integrated technology solutions allow growth-stage biotech and pharma companies to reduce timelines ...
Breaking Biology News(10 mins):
(Date:10/29/2019)... ... 29, 2019 , ... Modality Solutions, a biopharmaceutical ... chain validation workshop at the Biomanufacturing World Summit (BMWS19) Conference, November 11-12, 2019, ... Biomanufacturing World Summit brings together pharmaceutical executives, cutting-edge technology providers, and ...
(Date:10/26/2019)... ... October 24, 2019 , ... Sparks Marketing Group, ... (BMMG), a boutique healthcare-specific marketing firm, to strengthen the agency’s growing focus ... Division. , Healthcare clients in pharma, bio-therapeutics, medical device and healthcare technologies currently ...
(Date:10/22/2019)... ... , ... Catalent, a global leader in clinical supply services, today announced that ... in a panel session titled “Cell and Gene Therapy Logistics” at the upcoming Health ... on Oct. 28-30, 2019. , The panel session, on Wednesday, Oct. 30 at 8:30 ...
(Date:10/22/2019)... , ... October 22, 2019 , ... ... has announced that its lead program, DBI-001, met its primary safety endpoints, with ... labeled phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s ...
Breaking Biology Technology:
Cached News: